Black Titan (NASDAQ:BTTC – Get Free Report) posted its quarterly earnings data on Friday. The company reported ($0.10) EPS for the quarter, FiscalAI reports.
Black Titan Price Performance
NASDAQ BTTC traded down $0.00 on Friday, reaching $0.28. 99,591 shares of the stock traded hands, compared to its average volume of 4,003,637. The firm’s fifty day simple moving average is $0.43 and its 200 day simple moving average is $0.98. The company has a quick ratio of 4.62, a current ratio of 4.62 and a debt-to-equity ratio of 0.06. The company has a market cap of $3.02 million, a price-to-earnings ratio of -0.10 and a beta of 1.21. Black Titan has a 12 month low of $0.28 and a 12 month high of $10.05.
Black Titan Company Profile
Titan Pharmaceuticals, Inc is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.
Read More
- Five stocks we like better than Black Titan
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for Black Titan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Titan and related companies with MarketBeat.com's FREE daily email newsletter.
